Your browser doesn't support javascript.
Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2.
Mao, Ruichao; Bie, Lihua; Xu, Maofeng; Wang, Xiaocong; Gao, Jun.
  • Mao R; Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, Hubei 430070, China. gaojun@mail.hzau.edu.cn.
  • Bie L; Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, Hubei 430070, China. gaojun@mail.hzau.edu.cn.
  • Xu M; Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, Hubei 430070, China. gaojun@mail.hzau.edu.cn.
  • Wang X; Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, Hubei 430070, China. gaojun@mail.hzau.edu.cn.
  • Gao J; Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan, Hubei 430070, China. gaojun@mail.hzau.edu.cn.
Phys Chem Chem Phys ; 23(22): 12549-12558, 2021 Jun 09.
Article in English | MEDLINE | ID: covidwho-1233727
ABSTRACT
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters the host cell after the receptor binding domain (RBD) of the virus spike (S) glycoprotein binds to the human angiotensin-converting enzyme 2 (hACE2). This binding requires the RBD to undergo a conformational change from a closed to an open state. In the present study, a key pair of salt bridges formed by the side chains of K537 and E619, residues at the interfaces of SD1 and SD2, respectively, was identified to promote the opening of the RBD. Mutations of K537Q and E619D reduced their side chain lengths and eliminated this pair of salt bridges; as a result, the opening of the RBD was not observed in the MD simulations. Thus, blocking the formation of this pair of salt bridges is a promising approach for treating novel coronavirus disease 2019 (COVID-19). FDA approved drug molecules were screened by their capabilities of blocking the formation of the key pair of salt bridges, achieved by their positional stabilities in the cavity containing the side chains of K537 and E619 formed in the interface between SD1 and SD2. Simeprevir, imatinib, and naldemedine were identified to possess the desired capability with the most favorable interaction energies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Design / Spike Glycoprotein, Coronavirus / SARS-CoV-2 Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Phys Chem Chem Phys Journal subject: Biophysics / Chemistry Year: 2021 Document Type: Article Affiliation country: D1cp01045j

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Drug Design / Spike Glycoprotein, Coronavirus / SARS-CoV-2 Type of study: Prognostic study Topics: Traditional medicine Limits: Humans Language: English Journal: Phys Chem Chem Phys Journal subject: Biophysics / Chemistry Year: 2021 Document Type: Article Affiliation country: D1cp01045j